eBook:
Increasing Diversity in Clinical Trials: A Comprehensive Guide for Pharma Companies
Drive health equity by increasing diversity in your clinical trials.
The lack of diversity in clinical trials is one of the biggest obstacles to achieving true health equity. Despite making up a significant portion of the U.S. population, communities of color have historically been underrepresented in clinical research.
This lack of representation means treatments are not adequately tested on diverse populations, leading to skewed data, unfavorable health outcomes, rising healthcare costs, and a perpetuation of existing health inequalities.
The FDA has taken note, issuing new draft guidance that recommends pharmaceutical companies submit race and ethnicity diversity action plans for clinical trials—or risk delays. Building a robust strategy to improve diversity is now a necessity, as well as an ethical imperative.
Download this in-depth guide to gain a comprehensive understanding of clinical trial diversity challenges and solutions to drive health equity.
